Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib plus weekly paclitaxel versus weekly paclitaxel alone in recurrent ovarian, fallopian tube, or primary peritoneal cancer, with a preceding Phase 1 in ovarian or breast cancer
2009-011428-79Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of alisertib in Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC), primary peritoneal adenocarcinoma (PPC) and 1 more (3 arms), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Phase 1 primary endpoints. Started Jul 2012; status: completed.
02
Drugs
alisertib
03
Conditions
Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal adenocarcinoma (PPC)breast cancer
Beyond the preview
Go deeper on 2009-011428-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011428-79.